How effective is the treatment of DaliRasen Tablets? Real data and patient feedback

Daridorexant is a new drug for insomnia that has shown significant efficacy in clinical trials in recent years. It mainly acts on orexin receptors to regulate the balance of sleep and wakefulness in the brain, thereby helping to improve patients' sleep quality. How effective is DaliRasen in treating insomnia? Especially in placebo-controlled clinical trials, true efficacy and patient feedback are critical.

According to the data from two multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trials, DaliRasen has shown excellent efficacy in improving insomnia symptoms. Participants in the study were patients who met DSM-V diagnostic criteria for insomnia and had a high degree of insomnia severity. The trial results show that DaliRasen can significantly reduce the time it takes for patients to fall asleep and prolong their continuous sleep time. Specifically, patients' "wake time after sleep onset" (WASO) and "latency to sustained sleep" (LPS) were significantly shortened when using a 50 mg dose of DaliRasen, and patients' self-reported total sleep time was also significantly improved. These results indicate that DaliRasen has practical clinical significance in improving patients' sleep quality.

Compared with placebo, Both 25 mg and 50 mg of dalirasin significantly improved sleep quality, especially in reducing nighttime awakenings, extending sleep duration, and improving patients' sleep duration. Especially in Study 1, a 50 mg dose of dalilasen not only significantly improved WASO and LPS, but patients also had a significant decrease in self-reported sleepiness scores (IDSIQ sleepiness domain), showing that dalilasen can help alleviate daytime sleepiness problems caused by sleep disorders. However, in another study, although 25 mg of DaliRasen showed positive effects in improving WASO and self-reported sleep duration, the differences in LPS and IDSIQ scores did not reach statistically significant levels, which may be related to different trial designs or differences in patient populations.

In terms of drug tolerability, DaliRasen also showed good performance. Although some patients reported mild adverse reactions, such as nausea, headache, dizziness, and fatigue, the incidence of these side effects was relatively low and was tolerated by most patients. Compared with traditional sleep medications such as zolpidem, the incidence of side effects is significantly lower, indicating that it is better tolerated in long-term use.

It is worth mentioning that DaliRasen also shows flexibility in dosage adjustment. In another double-blind clinical trial involving 1,005 subjects, different doses of 5mg, 10mg, 25mg and 50mg significantly improved patients' WASO and LPS. These results show that DaliRasen is effective at multiple dose levels, and patients and doctors can adjust the dose according to individual circumstances to achieve the best therapeutic effect.

Overall, DaliRasen has broad application prospects in the treatment of insomnia. Through the verification of multiple clinical trials, DaliRasen has been proven to have significant efficacy in improving insomnia symptoms, and is well tolerated and has mild side effects. Patient feedback also shows that the sleep quality of many insomnia patients has been significantly improved after using DaliRasen. Nonetheless, patients should have detailed communication with their doctor before using this drug to ensure safe use and maximize efficacy. With the accumulation of clinical data and further research on this drug, DaliRasen is expected to become a new generation of drugs for the treatment of insomnia.

Reference materials:https://www.quviviq.com/